Payer Perceptions of the Inflation Reduction Act
Lumanity convened medical and pharmacy directors from six large national and regional US payers with at least 25% Medicare business to share their perspectives on both the Maximum Fair Price (MFP) drug price negotiation and Part D redesign components of the IRA. Read the six key insights from our panel.
View Aug 28, 2023